ABIONYX Pharma SA (LON: 0RAG)

Market Cap	37.19M
Revenue (ttm)	4.12M
Net Income (ttm)	-2.85M
Shares Out	n/a
EPS (ttm)	-0.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2
Average Volume	553
Open	1.320
Previous Close	n/a
Day's Range	1.320 - 1.320
52-Week Range	0.763 - 1.194
Beta	0.29
RSI	56.16
Earnings Date	Mar 6, 2025

About ABIONYX Pharma

ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. It develops CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteine...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2005
• Employees: 61
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RAG

Financial Performance

In 2023, ABIONYX Pharma's revenue was 4.64 million, a decrease of -11.65% compared to the previous year's 5.25 million. Losses were -3.52 million, -16.36% less than in 2022.

Financial numbers in EUR